Otezla divestiture makes next launches mission critical for BMS

The molecule that started Celgene's market decline, leading to its eventual takeout, is now being off-loaded to allow BMS to close the deal. Losing it from the line-up will raise the pressure for successful launches of the new assets.

On Monday, Bristol-Myers Squibb Co. (NYSE:BMY) said it would divest psoriasis drug Otezla apremilast based on an FTC review of the proposed $74 billion acquisition of Celgene Corp.(NASDAQ:CELG).

The divestment will remove a drug

Read the full 712 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers